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Abstract
Rationale—Pharmacological manipulations of the type 1 cannabinoid receptor (CB1) suggest a
role for CB1 in morphine-induced antinociception, but studies utilizing CB1 knockout (KO) mice
do not support this conclusion. Since studies using CB1 KO mice to study morphine’s
antinociceptive effects have only examined thermal nociception, this study examines these
interactions in models that employ a chemical stimulus.
Objectives—To determine whether the findings obtained with thermal pain models extend to
other models, the effects of morphine on acetic acid-induced writhing were examined in CB1 KO
and wildtype (WT) mice. Behaviors that decrease in response to acid injection, feeding and wheel-
running, were also examined, and investigations were carried out in the thermal hotplate assay.
The CB1 antagonist SR141716A was also examined in these assays.
Results—Morphine completely blocked acid-induced writhing (1.0 – 10.0 mg/kg) and increased
response latencies in the hotplate (10.0 - 32.0 mg/kg) in both genotypes. Morphine (3.2 mg/kg)
significantly attenuated the suppression of wheel-running but did not completely prevent this
effect in either genotype. Morphine did not alter pain-suppressed feeding. In each of these assays,
morphine’s effects were not altered in CB1 KO mice compared to WT mice, however,
SR141716A attenuated morphine’s effects in C57BL/6 mice.
Conclusions—The effects of morphine do not differ in CB1 KO and WT mice in preclinical
pain models using thermal and chemical stimuli. Since SR141716A did attenuate the effects of
morphine, it is possible that CB1 KO mice undergo developmental changes that mask the role of
CB1 receptors in morphine’s antinociceptive effects.
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INTRODUCTION
The cannabinoid and opioid systems include G-protein-coupled receptors, type 1
cannabinoid (CB1) and μ-opioid receptors, respectively, that have parallel distribution
throughout the CNS. The activation of these receptors produce similar effects such as
decreased cyclic AMP and inhibition of synaptic activity (Pertwee 2006; Waldhoer et al.
2004). Further, agonists of CB1 receptors and μ-opioid receptors produce similar behavioral
effects that include antinociception (Cox and Welch 2004), alterations of locomotor activity
(Pascual et al. 2005; Smith et al. 2009), food consumption (Jarbe and DiPatrizio 2005; Li et
al. 2006), and thermoregulation (Diaz et al. 2009; Wang et al. 2009). Moreover, agonists at
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these receptors serve as reinforcers in self-administration paradigms (Justinova et al. 2008;
Negus and Rice 2009).
Numerous studies have examined the interactions of these systems, and antinociception is
one area in which interactions have been consistently reported. The cannabinoid agonist
delta-9-tetrahydrocannabinol (Δ9-THC) potentiates the effects of morphine in the mouse
tail-flick test (Cichewicz and McCarthy 2003) and the rat paw pressure test (Cox et al.
2007). There is also evidence that endogenous cannabinoids modulate the effects of opioids.
The CB1 antagonist AM251 blocks morphine-induced antinociception as measured by an
inflammatory pain model (Pacheco et al. 2008) and the tail-flick test in mice (Pacheco et al.
2009). Methylarachidonoylflurophosphate (MAFP), which inhibits the degradation of the
endogenous cannabinoids anandamide (AEA), and 2-arachidonoylethanolamine (2-AG),
enhances the effects of morphine (Pacheco et al. 2009), as does administration of AEA in
combination with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (Haller et al.
2008).
Although studies utilizing pharmacological manipulations of cannabinoid signaling suggest
a role for endogenous cannabinoids in the antinociceptive effects of opioids, the results of
research with genetic models do not. Specifically, morphine is equally effective in CB1
knockout (KO) and wildtype (WT) mice in the hotplate and tail immersion assays (Ledent et
al. 1999; Valverde et al. 2000). It is noteworthy that a variety of pain models have been used
in studies utilizing pharmacological manipulations to examine cannabinoid-opioid
interactions (Cox et al. 2007; Pacheco et al. 2008, 2009) and in studies phenotyping CB1
KO mice (Ledent et al. 1999; Zimmer et al. 1999). In contrast, studies assessing the
antinociceptive effects of morphine in CB1 knockout mice have only examined behaviors
that occur in response to acute presentation of thermal noxious stimuli (Ledent et al. 1999;
Valverde et al. 2000).
The mechanisms underlying nociception and antinociception depend on factors such as the
modality and duration of the noxious stimuli (Mogil 2009) as well as the behavioral
endpoints that are used to measure the pain response (Le Bars et al 2001). This being the
case, the current studies extend the existing research on interactions between the
cannabinoid and opioid systems by examining CB1 KO and WT mice in preclinical tonic
pain assays that employ chemical noxious stimuli and measure behavioral responses that
either decreased or increased in response to exposure to noxious stimuli. Specifically, we
examined the effects of morphine on the behavioral consequences of intraperitoneal
injection of acetic acid in CB1 KO and WT mice. We sought to determine the role of the
CB1 receptor in the effects of morphine on the writhing response to acetic acid injection,
and on behaviors that decrease in response to acetic acid injection, namely feeding and
wheel-running (pain-suppressed behaviors). CB1 KO and WT were also used to determine
the effects of morphine in a thermal (hotplate) assay for comparison.
In addition to the noxious stimulus modality and duration, another variable that might
account for the dissimilar results obtained from studies using CB1 KO mice and antagonists
is that constitutive inactivity of CB1 in the KO animals might produce changes that mask the
role of this receptor in the effects of morphine. Accordingly, SR141716A, a CB1 antagonist,
was used to determine the effects of acute disruption of CB1 activity on morphine
antinociception.
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Male and female CB1 KO mice and age-matched WT littermates were used for these
experiments (total animal numbers: female KO = 49, male KO = 52, female WT = 51, and
male WT = 51). The distribution of males and females was balanced across groups except in
instances where there were an odd number of mice, in which case males outnumbered
females by 1. Mice were generated on a full C57BL/6 background (Zimmer et al. 1999) and
heterozygous breeding pairs were obtained from Virginia Commonwealth University. Due
to limited access to CB1 KO and WT mice, male C57BL/6 mice were used in studies
examining morphine in combination with SR141716A. All mice were bred and housed in
the animal facilities of the Department of Psychology at the University of North Carolina at
Chapel Hill. Mice were group housed after weaning and were subsequently individually
housed where specified by the experimental protocols. Mean (SEM) mouse weights at the
time of testing were as follows: female KO = 19.89 (0.69) g, male KO = 24.09 (0.57) g,
female WT = 21.42 (0.30) g and male WT = 26.73 (0.57) g. Mean (SEM) weight for
C57BL/6 mice was 27.83 (0.43) g.
Mice had free access to food and water except where specified by the experimental
protocols below. Lights were programmed on a 12 hour light/dark cycle with lights off at
7:00am. All experiments took place during the dark cycle. Animal protocols were approved
by the institutional animal care and use committee, and the methods were in accord with the
“Guide for the Care and Use of Laboratory Animals” (Institute of Laboratory Animal
Research, Division on Earth and Life Studies, National Research Council, 2010)
Experimental Procedures
Assays of pain-elicited behavior
Hotplate—Mice were group housed and had free access to food and water for these
experiments. Prior to testing mice were habituated to the testing room and handling for two
days. On the test day antinociception was assessed using a hotplate analgesia meter (25.3 X
25.3 cm; Columbus Instruments, Columbus, OH). During the hotplate assay the mouse was
placed onto the surface of the apparatus and the latency to lick or flutter the hind paws, or to
jump from the hotplate surface was recorded. Responses were measured to the nearest 0.1 s
and predetermined cutoff time of 20 s was defined as the maximum trial duration in order to
prevent tissue damage. Immediately following termination of a trial, whether due to an
animal’s response or the fact that the cutoff time elapsed, mice were removed from the
apparatus and returned to the home cage.
Baseline latencies were assessed in CB1 KO and WT mice (n = 12 of each genotype) across
a range of hotplate temperatures (44–56±0.1°C). Temperatures were tested in ascending
order and 15 min elapsed between trials. One week later the same mice were used to assess
the effects of morphine using a hotplate temperature of 56±0.1°C. Responses were measured
30 and 15 min prior to drug administration and the latencies from these trials were averaged
to yield one baseline value. During dose-effect determination, cumulative doses of morphine
were administered 30 min apart in half log increments. Temperatures and doses were
examined in a repeated measures fashion. The effect of each dose of morphine is expressed
as the percentage of the maximum possible effect (%MPE): [postdrug latency (s) – baseline
latency (s)]/[20 – baseline latency (s)].
To determine the consequences of pretreatment with the CB1 antagonist SR141716A on
morphine antinociception, C57BL/6 mice were tested at 56º C as described above. Morphine
(32.0 mg/kg) and SR141716A (3.0 mg/kg) were administered alone and in combination 30
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and 60 min prior to testing, respectively. These doses were selected based on prior work in
our laboratory with these compounds in this mouse strain.
Acetic acid-induced writhing—Mice were group housed and had free access to food
and water until 12 and 5 h prior to testing, respectively. Mice were habituated to the testing
room and handling for two days prior to testing. In addition, mice were given a 30 min
session with free access to 32% liquid nutrition (Vanilla flavor, CVS brand) on the day prior
to testing. Food and water deprivation and access to liquid nutrition occurred due to the fact
that data for acetic acid-suppressed feeding were collected in these animals during the same
session (see below).
On the test day, separate groups of mice were injected with saline or morphine (0.1 – 10.0
mg/kg) 45 min prior to the start of the test session (n = 5–6 of each genotype per group).
Immediately prior to the test session, mice were injected with saline or 0.56% acetic acid.
Following the second injection mice were immediately placed into clean polycarbonate
mouse cages (29.91 X 19.05 X 12.7 cm; Allentown Inc, Allentown, NJ) containing dishes of
32% liquid nutrition, and their behavior was videotaped for 30 min. Following the session,
the tapes were viewed and the number of writhes was recorded. Writhes were operationally
defined as an elongation of the body with simultaneous extension of the hind limbs. The
effect of each dose of morphine is expressed as percent inhibition of writhing (% Inhibition):
[((writhes in saline treated mice/writhes in morphine treated mice)/writhes in saline treated
mice) X 100].
To determine the consequences of pretreatment with the CB1 antagonist SR141716A on
morphine antinociception in the writhing assay, C57BL/6 mice were tested as described
above. Morphine (3.2 mg/kg) and SR141716A (3.0 mg/kg) were administered alone and in
combination 45 and 60 min prior to testing, respectively. These doses were selected based
on prior work in our laboratory with these compounds in this mouse strain.
Assays of pain-suppressed behavior
Acetic acid-suppressed feeding—Mice were group housed and had free access to food
and water until 12 and 5 h prior to testing, respectively. Mice were habituated to the testing
room and handling for two days prior to testing. In addition, 24 h prior to testing, mice were
given a 30 min session of free access to approximately 14 ml of 32% liquid nutrition
(Vanilla flavor, CVS brand; composition as used: protein = 0.36 g/oz, carbohydrate = 1.6 g/
oz, and fat = 0.24 g/oz) in order to reduce the novelty of the substance. During this session,
individual mice were placed into bedding-free polycarbonate mouse cages (29.91 X 19.05 X
12.7 cm; Allentown Inc, Allentown, NJ) that contained a glass dish containing liquid
nutrition and were allowed to explore the testing environment and consume the liquid
nutrition.
On the test day, separate groups of mice were injected with saline or morphine (0.1 – 10.0
mg/kg) 45 min prior to the start of the test session (n = 5–6 of each genotype per group).
Immediately prior to the test session, mice were injected with 0.56% acetic acid or saline.
Following the second injection mice were immediately placed into clean polycarbonate
mouse cages (29.91 X 19.05 X 12.7 cm; Allentown Inc, Allentown, NJ) containing liquid
nutrition and the amount of liquid consumed was measured for 30 min. Consumption was
quantified by subtracting the weight of the liquid-containing dishes after the session from
the weight obtained prior to the session. Because body size might influence consumption
independent of other variables, this value was divided by the animals’ weight (grams of
liquid consumed per gram of body weight). In the event of spillage, the data were discarded.
The effect of each dose of morphine on pain-suppressed consumption is expressed as
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percent of non-suppressed consumption (% Control): [(acetic acid-suppressed consumption
(g/g)/non-suppressed consumption (g/g)) X 100].
To determine the consequences of pretreatment with the CB1 antagonist SR141716A on
morphine antinociception in the pain-suppressed feeding assay, C57BL/6 mice were tested
as described above. Morphine (3.2 mg/kg) and SR141716A (3.0 mg/kg) were administered
alone and in combination 45 and 60 min prior to testing, respectively. The effects of 3.0 mg/
kg SR141716A on non-suppressed feeding were also determined. These doses were selected
based on prior work in our laboratory with these compounds in this mouse strain.
Acetic acid-suppressed wheel-running—Mice were grouped housed in standard
polycarbonate mouse cages (29.91 X 19.05 X 12.7 cm; Allentown Inc, Allentown, NJ) until
the start of these experiments. At this time mice were individually housed in polycarbonate
cages (35.56 X 26.67 X 13.97 cm; Tecniplast USA Inc., Exton, PA) containing running
wheels (ENV-044, Med Associates, St. Albans, VT). Testing occurred after three weeks of
habituation to handling and acquisition of wheel-running behavior. On the day prior to
testing (control session) mice were injected with saline followed 45 min later by a second
injection of saline. The next day (test session), 24 h after the control session, separate groups
of mice were injected with morphine (0.32 – 3.2 mg/kg) or saline and 45 min later were
injected with 0.56% acetic acid or saline (n = 6–7 of each genotype per group). Wheel-
running was recorded for 30 min following the second injection (acetic acid or saline)
during the control and test sessions. The effect of each dose of morphine on pain-suppressed
wheel-running is expressed as percent of non-suppressed wheel-running (% Control):
[(acetic acid-suppressed running/non-suppressed running) X 100].
To determine the consequences of pretreatment with the CB1 antagonist SR141716A on
morphine antinociception in the pain-suppressed wheel-running assay, C57BL/6 mice were
tested as described above. Morphine (1.0 mg/kg) and SR141716A (3.0 mg/kg) were
administered alone and in combination 45 and 60 min prior to testing, respectively. The
effects of morphine and SR141716A on non-suppressed running were also determined.
These doses were selected based on prior work in our laboratory with these compounds in
this mouse strain.
Drugs
Morphine sulphate and SR141716A were provided by the National Institute on Drug Abuse
(Bethesda, MD, USA). Morphine was dissolved in 0.9% saline and SR141716A was
dissolved in a vehicle of 100% ethanol, Alkamuls EL-620 (Rhodia, Cranbury, New Jersey)
and saline in a ratio of 1:1:18. Acetic acid was purchased from Fischer Scientific and diluted
in 0.9% saline. Morphine and SR141716A were injected subcutaneously and acetic acid was
injected intraperitoneally at a volume of 0.1 ml/10 g.
Data Analysis
No sex differences were detected in these studies and all data analyses that follow were
conducted with groups collapsed across this variable. Data are presented as raw values
(±SEM) or expressed as mean (±SEM) % MPE, % Inhibition, or % Control depending on
the assay (see above). The morphine dose required to produce a 50% maximal effect (ED50)
was derived using log-linear interpolation when possible, and differences in morphine
potency between genotypes were determined and expressed as a potency ratio with 95%
confidence limits. Two-factor analyses of variance (ANOVA) were performed to determine
the effects of genotype and dose. Student’s t-tests were used when appropriate to determine
genotypic differences and the effects of SR141716A under control conditions. In studies
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examining the effects of pretreatment with SR141716A on morphine antinociception, one-
way ANOVA with Bonferoni comparisons were used to determine treatment effects. All
statistical analyses were conducted with an alpha level of significance set at p < 0.05.
RESULTS
Fig. 1 (top) shows the response latencies for CB1 KO and WT mice across a range of
temperatures (44–56±0.1°C) on the hotplate. Two-factor ANOVA revealed temperature
dependent decreases in response latencies [F(4,110) = 296.66, p < 0.05]. However, there
were no genotypic differences in response latencies and there was no interaction between
genotype and temperature. Baseline responses at 56 º did not differ between assessments
during the temperature effect curve or morphine dose-effect curve. Morphine (Fig. 1
bottom) produced dose-dependent antinociception on the 56º C hotplate [F(3,66) = 174.18, p
< 0.05] in CB1 KO [ED50 (95% CL) = 7.35 (5.99–9.01)] and WT mice [ED50 (95% CL) =
8.37 (6.97–10.05)] but there were no differences in the effects of morphine between
genotypes [potency ratio = 1.11 (0.85–1.45)], and no significant interaction of morphine and
genotype.
Fig. 2 shows the effects of morphine (32.0 mg/kg) and SR141716A (3.0 mg/kg) alone and in
combination in the hotplate assay at 56º C in C57BL/6 mice. One-way ANOVA revealed a
significant effect of treatment [F(3,32) = 111.02, p < 0.05] and bonferoni comparisons show
that SR141716A had no effect on hotplate latency. Morphine produced a 100% maximum
possible effect in all animals tested (p < .05 vs saline) whereas pretreatment with
SR141716A significantly attenuated the effects of morphine (p < .05 vs morphine alone),
though there was still a significant antinociceptive effect (p < .05 vs saline).
Fig. 3 (top) shows the number of writhes produced by acetic acid in CB1 KO and WT mice
in the absence of morphine. KO mice writhed significantly more [28±4.1] than WT mice
[15±4.1] in response to acetic acid [t(10) = 2.2, p < 0.05]. The raw data (number of writhes;
Fig. 2 bottom inset) indicate that these genotypic differences persisted when morphine was
administered prior to acetic acid [F(1,50) = 16.47, p < 0.05]. However, when basal
genotypic differences were taken into account by expressing the data as percent inhibition of
writhing (Fig. 3 bottom), morphine dose-dependently inhibited writhing [F(4,50) = 28.99, p
< 0.05] in CB1 KO [ED50 (95% CL) = 0.37 (0.27–0.51)] and WT mice [ED50 (95% CL) =
0.34 (0.17–0.66)] and there were no differences in the effects of morphine between
genotypes [potency ratio = 1.13 (0.61–2.13)]; there was no significant interaction of
genotype and dose.
Fig. 4 shows the effects of 3.2 mg/kg morphine and 3.0 mg/kg SR141716A, alone and in
combination on acetic acid induced writhing in C57BL/6 mice. One-way ANOVA revealed
a significant effect of treatment [F(3,20) = 23.90, p < 0.05] such that SR141716 produced a
slight but non-significant increase in writhes. Morphine significantly inhibited writhing (p
< .05 vs saline) and this effect was attenuated by pretreatment with SR141716A (p < 0.05 vs
saline).
Fig. 5 (top) shows the effects of saline and 1.0 mg/kg morphine on liquid nutrition
consumption in CB1 KO and WT in the absence of acetic acid. There was a main effect of
genotype [F(1,21) = 9.16, p < 0.05] where WT mice consumed more liquid nutrition than
KO mice, but 1.0 mg/kg morphine had no effect on non-suppressed feeding and there was
not a significant interaction between genotype and treatment. Intraperitoneal injection of
acetic acid almost completely suppressed consumption in both genotypes [WT: 0.008±0.002
g/g; KO: 0.007±0.001 g/g]. Morphine (Fig. 5 bottom) was not effective at attenuating acetic
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acid-induced suppression of consumption. Table 1 shows raw consumption (ml) for each
genotype.
Pretreatment with 3.0 mg/kg SR141716A (Fig. 6 (top)) decreased consumption of ensure by
C57BL/6 mice in the absence of acetic acid (i.e. consumption not suppressed by pain; t (5) =
2.38, p < .05). Figure 6 (bottom) shows that neither 3.2 mg/kg morphine nor 3.0 mg/kg
SR141716A, alone or in combination, altered consumption that was suppressed by acetic
acid injection.
Fig. 7 (top) shows the effects of saline and 3.2 mg/kg morphine on wheel-running behavior
in CB1 KO and WT mice in the absence of acetic acid. There was a main effect of genotype
[F(1,20) = 9.36, p < 0.05] where WT mice displayed higher levels of wheel-running than
KO mice, however 3.2 mg/kg morphine had no effect on non-suppressed wheel-running and
there was no significant interaction between genotype and treatment. Fig. 7 (bottom inset)
shows that intraperitoneal injection of acetic acid completely suppressed wheel-running in
both genotypes. Morphine significantly attenuated the suppression of wheel-running by
injection of acetic acid [F(4,53) = 6.03, p < 0.05] and the genotypic differences seen with
non-suppressed wheel-running persisted with WT mice displaying higher levels of wheel-
running than KO mice [F(1,53) = 5.10, p < 0.05]; there was no significant interaction of
morphine and genotype. When basal genotypic differences in wheel-running were taken into
account by expressing wheel-running as percentage of control running, the effects of
morphine on acetic acid-suppressed wheel running did not differ between genotypes.
Morphine ED50 (95% CL) = 1.72 (0.77–3.79) for KO mice and 1.38 (0.84–2.25) for WT
mice [potency ratio = 1.18 (0.51–2.94)].
Fig. 8 (top) shows that when administered in the absence of acetic acid, morphine and
SR141716A, alone and in combination, do not alter wheel running behavior in C57BL/6
mice. The bottom portion of Fig.8 shows the effects of morphine, alone and in combination
with SR141716A, on pain-suppressed wheel running. One-way ANOVA revealed a
significant effect of treatment [F(2,19) = 10.44, p < 0.05], such that mice treated with
morphine produced significantly more wheel revolutions than mice treated with saline (p < .
05 vs saline). Pretreatment with SR141716A blocked this effect (p < 0.5 vs morphine alone).
DISCUSSION
The primary goal of these experiments was to investigate the role of the CB1 receptor in the
antinociceptive effects of morphine in CB1 KO mice. Previous studies have shown that CB1
KO and WT mice respond similarly in models of acute thermal pain. In the present study,
we extended these findings by determining the effects of morphine in CB1 KO and WT
mice in models examining pain resulting from i.p. injection of acetic acid. These models
allow for the assessment of both pain-elicited behaviors (writhing) and pain-suppressed
behaviors (food consumption and wheel-running). In addition, we compared the results seen
in CB1 KO and WT mice with results obtained with the CB1 antagonist, SR141716A in
C57BL/6 mice.
The two genotypes did not differ in their responses on the hotplate across temperatures that
ranged from innocuous to noxious (44–56±0.1°C). This suggests that CB1 receptors are not
integral to this behavioral response to thermal noxious stimuli. Previous research has
revealed mixed results with regard to nociceptive responding in the hotplate assay between
CB1 KO and WT mice. In a study utilizing mice on the same background as used in the
present study (C57BL/6), CB1 KO mice were found to have increased latencies (interpreted
as hypoalgesia) relative to WT mice (Zimmer et al. 1999). Consistent with the data obtained
Miller et al. Page 7













in the present study, studies utilizing mice on a CD1 background showed no differences
between genotypes (Ledent et al. 1999; Valverde et al. 2000).
Previous studies have obtained mixed results when examining the effects of CB1 antagonists
on responses to acute thermal pain with some studies revealing no effect (Cravatt et al.
2001) and others suggesting a hyperalgesic effect (Richardson et al. 1998). The present
findings are consistent with the former in that, at the dose tested, SR141716A did not alter
hotplate latencies.
That there were no differences between CB1 KO and WT mice in response to morphine in
the hotplate assay suggests that the absence of functioning CB1 receptors does not alter the
effects of morphine in this context. Pretreatment with SR141716A, however, did produce a
modest but significant attenuation of the antinociceptive effects of morphine in the hotplate
assay. This finding is consistent with other data that suggest that CB1 receptors do modulate
the effects of morphine (Pacheco et al. 2008, 2009). Taken together, these findings suggest
that CB1 KO and WT mice respond similarly to morphine because of differences in the
consequences of constitutive inactivity of CB1 and the acute effects of a CB1 receptor
antagonist. It might be the case that the knockout mice undergo unidentified developmental
changes that mask the role of CB1 receptors in the effects of morphine.
In order to determine if the findings of studies using acute thermal pain extend to other
stimulus modalities and durations, experiments were conducted with acetic acid serving as a
tonic, chemical noxious stimulus. Acetic acid (0.56%) produced more writhes in CB1 KO
mice than in CB1 WT mice, suggesting a role for CB1 receptors in the writhing response to
acetic acid. Other findings also suggest a role for CB1 receptors in responses to chemical
noxious stimuli. For instance, disruption of FAAH activity by pharmacological or genetic
means inhibits acetic acid-induced writhing (Naidu et al. 2009), and inhibition of CB1
signaling results in hyperalgesia in the formalin test (Calignano et al. 1998). On the other
hand, studies utilizing CB1 KO and WT mice on a CD1 background (Ledent et al. 1999;
Valverde et al. 2000) found no differences between genotypes in the writhing test. At the
dose tested in the present experiments, the CB1 antagonist SR141716A did not alter the
number of writhes elicited by acetic acid which is consistent with other findings (Booker et
al. 2009).
Morphine dose-dependently decreased the number of writhes that resulted from
intraperitoneal injection of acetic acid, and there were no genotypic differences in the effects
of morphine in this assay. This suggests that results obtained in other studies utilizing acute
thermal pain to study the antinociceptive effects of morphine in CB1 knockout mice extend
to this commonly used model of tonic pain. On the other hand, pretreatment with
SR141716A attenuated the ability of morphine to inhibit the writhing response, again
suggesting that morphine’s effects are modulated by CB1, but this role is masked in CB1
knockout mice.
Nociception elicits pain-related behaviors and suppresses other behaviors. Research has
demonstrated the utility of preclinical pain assays that measure pain-suppressed behavior in
addition to traditional assays that measure pain-elicited behavior (Martin et al. 2005; Matson
et al. 2007; Negus et al. 2010; Pereira Do Carmo et al. 2009; Stevenson et al. 2006, 2009).
Consequently, the present studies also used CB1 KO and WT mice to determine the role of
the endogenous cannabinoid system in morphine’s effects on behaviors that are suppressed
by exposure to noxious stimuli.
Consumption of palatable food, a behavior that occurs at a high rate under control
conditions, is decreased upon exposure to noxious stimuli (Stevenson et al. 2006). In the
present studies, control consumption was decreased in mice lacking CB1. This finding,
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along with the finding that SR141716A decreased non-suppressed food consumption is
consistent with research indicating that the cannabinoid system is an important mediator of
feeding behaviors. Other studies assessing feeding behavior in CB1 KO mice have revealed
results similar to those found here (Cota et al. 2003). Moreover, it has been shown that CB1
agonists and antagonists produce hyperphagia (Miller et al. 2004) and hypophagia (Ward et
al. 2009), respectively.
In contrast to findings obtained from studies utilizing C57BL/6J mice (Stevenson et al.
2006), in the current study morphine was not effective at attenuating the suppression of
feeding by i.p. injections of acetic acid. That morphine had no effect on non-suppressed
consumption suggests that it is unlikely that this result is due to suppression of consumption
by morphine. The reasons for the discrepancies between the present studies and the
Stevenson et al. (2006) study are unclear, but there were numerous differences in
experimental parameters between the two studies (e.g. amount of exposure to acetic acid and
food) that might contribute to the dissimilar findings.
Wheel-running also occurs at a high rate in rodents, and is susceptible to suppression by
noxious stimuli. Under baseline conditions, CB1 KO mice exhibited less wheel-running
behavior than WT mice which is consistent with other findings (Dubreucq et al. 2010). The
CB1 antagonist CB1 antagonist, SR141716A, did not reduce wheel-running when
administered to C57BL/6 mice though it has been shown to do so in rats (Keeney et al.
2008). The findings in CB1 KO mice might suggest a role of the endocannabinoid system in
the reinforcing effects of wheel-running, but it might also be the case that the differences
seen in the present studies are related to other effects of CB1 knockout. For instance, the
decreased caloric intake by CB1 KO mice, demonstrated by others (Cota et al. 2003) and
suggested by the present feeding experiments, might lead to decreased wheel-running
behavior.
Unlike the results observed in the pain-suppressed feeding assay, morphine dose-
dependently attenuated the suppression of wheel-running behavior after i.p. injection of
acetic acid. These findings are consistent with previous reports showing that opioids are
effective at blocking decreases in a variety of behaviors that result from exposure to noxious
stimuli (Martin et al. 2005; Matson et al. 2007; Negus et al. 2010; Pereira Do Carmo et al.
2009; Stevenson et al. 2006, 2009). This suggests that under these conditions, morphine
reduces nociception in a manner that not only decreases reflexive responses to i.p. injection
of acetic acid (i.e. writhing), but restores rates of pain-suppressed spontaneous behavior. In
addition, 3.2 mg/kg morphine, which produced the peak effect on pain-suppressed wheel-
running in CB1 KO and WT mice, had no effect on non-suppressed wheel-running. This
suggests that the present results are not due to non-specific increases in wheel-running as a
result of morphine administration. As stated above, there were no genotypic differences in
the effects of morphine on suppressed or non-suppressed wheel-running. On the other hand,
as was the case in the other models used here, SR141716A significantly attenuated the
ability of morphine to block the suppression of wheel-running by acetic acid injection, again
suggesting a role for CB1 receptors in the antinociceptive effects of morphine in this assay.
The findings of the present studies are consistent with research demonstrating that CB1 KO
and WT mice do not respond differently to morphine on endpoints related to antinociception
(Ledent et al. 1999; Valverde et al. 2000). Moreover, the findings with SR141716A are
consistent with other studies that demonstrate a reduction of the antinociceptive effects of
morphine upon administration of CB1 antagonists (Pacheco et al. 2008, 2009). Combined
administration of anandamide and a selective inhibitor of its degradation enhanced the
effects of morphine (Haller et al. 2008), and Pacheco et al. (2009) also showed that MAFP,
which non-selectively inhibits the catabolism of AEA and 2-AG, enhanced the effects of
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morphine. These authors also demonstrated that a CB2 antagonist did not alter the effects of
morphine, and it has been demonstrated that the effects of MAFP are mediated via CB1
(Ates et al. 2003).
In the context of the literature, the present results demonstrating attenuation of morphine’s
effects by the CB1 antagonist, SR141716A, suggest that endogenous cannabinoids are
involved in the antinociceptive effects of morphine in models of acute thermal pain and
chemical pain. The mechanisms of these interactions are not clear. Researchers have
hypothesized that one factor in cannabinoid/opioid interactions is that exposure to
cannabinoids and opioids results in reciprocal changes in receptor expression and/or
function, and there is evidence that these systems do interact in this manner (e.g. Vigano et
al. 2005). Another possible mechanism behind opioid/cannabinoid interactions is that
activity at opioid and cannabinoid receptors may elevate levels of endogenous cannabinoids
and opioids, respectively. For instance, there is evidence that cannabinoid agonists elevate
dynorphin levels (Mason et al. 1999) and that morphine elevates anandamide levels (Vigano
et al 2004), but more data are needed to determine the significance of these effects. The
finding that morphine-induced antinociception does not differ in CB1 KO and WT mice
indicates that the constitutive absence of CB1 signaling may result in compensatory changes
that mask this receptor’s role in the antinociceptive effects of morphine.
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Hotplate assay for CB1 KO and WT mice. Top, temperature-effect curves (44–56 ºC) in the
absence of morphine. Abscissa: hotplate temperature (ºC). Ordinate: mean response latency
in seconds. Bottom, morphine dose-effect curves (1.0 – 32.0 mg/kg) on 56º C hotplate.
Abscissa: dose of morphine in milligrams per kilogram. Ordinate: percent maximum
possible effect
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Effect of the CB1 antagonist SR141716A on morphine antinociception in the hotplate assay
in C57BL/6 mice. Abscissa: treatment. Ordinate: mean response latency in seconds. Asterisk
denotes statistical significance compared with saline. Double asterisk denotes statistical
significance compared with morphine alone
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Acetic acid-induced writhing in CB1 KO and WT mice. Top, writhing in response to
intraperitoneal injection of 0.56% acetic acid. Ordinate: mean number of writhes. Asterisk
denotes statistical significance compared with WT (p<0.05). Bottom, effects of morphine on
writhing expressed as percent inhibition of writhing. Abscissa: dose of morphine in
milligrams per kilogram. Ordinate: percent inhibition of writhing. Bottom inset, effects of
morphine on writhing (raw data)
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Effect of the CB1 antagonist SR141716A on morphine antinociception in the writhing assay
in C57BL/6 mice. Abscissa: treatment. Ordinate: mean number of writhes. Asterisk denotes
statistical significance compared with saline. Double asterisk denotes statistical significance
compared with morphine alone
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Acetic acid-suppressed feeding in CB1 KO and WT mice. Top, non-suppressed feeding after
saline and 1.0 mg/kg morphine. Ordinate: mean grams consumed per gram of body weight.
Asterisk denotes statistical significance compared with WT (p<0.05). Bottom, effects of
morphine on acetic acid-suppressed feeding expressed as percent control. Abscissa: dose of
morphine in milligrams per kilogram. Ordinate: percent control consumption. Bottom inset,
effects of morphine on acetic acid-suppressed feeding (raw data)
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Effect of the CB1 antagonist SR141716A on morphine antinociception in the feeding assay
in C57BL/6 mice. Top, non-suppressed feeding after saline and 3.0 mg/kg SR141716A.
Abscissa: treatment. Ordinate: mean grams consumed per gram of body weight. Asterisk
denotes statistical significance compared with saline. Bottom, morphine alone and in
combination with SR141716A. Abscissa: treatment. Ordinate: mean grams consumed per
gram of body weight
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Acetic acid-suppressed wheel-running in CB1 KO and WT mice. Top, non-suppressed
wheel-running after saline and 3.2 mg/kg morphine. Ordinate: mean wheel revolutions.
Asterisk denotes statistical significance compared with WT (p<0.05). Bottom, effects of
morphine on acetic acid-suppressed wheel-running expressed as percent control. Abscissa:
dose of morphine in milligrams per kilogram. Ordinate: percent control running. Bottom
inset, effects of morphine on acetic acid-suppressed wheel-running (raw data)
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Effect of the CB1 antagonist SR141716A on morphine antinociception in the wheel-running
assay in C57BL/6 mice. Top, non-suppressed running after saline, 1.0 mg/kg morphine and
3.0 mg/kg SR141716A. Abscissa: treatment. Ordinate: mean wheel revolutions. Bottom,
morphine alone and in combination with SR141716A. Abscissa: treatment. Ordinate: mean
wheel revolutons. Asterisk denotes statistical significance compared with saline. Double
asterisk denotes statistical significance compared with morphine alone
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Table 1
Mean (SEM) liquid nutrition consumption (ml), unadjusted for weight, by CB1 KO and WT mice.
Treatment KO WT
Control 1.26 (0.18) 2.05 (0.01)
Saline 0.15 (0.02) 0.22 (0.05)
 0.1 mg/kg 0.25 (0.03) 0.22 (0.05)
 0.32 mg/kg 0.18 (0.02) 0.25 (0.03)
 1.0 mg/kg 0.15 (0.02) 0.47 (0.23)
 3.2 mg/kg 0.26 (0.03) 0.58 (0.32)
10.0 mg/kg 0.17 (0.02) 0.23 (0.03)
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